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Abstract: The substantial reduction in ischemic events provided by the dual antiplatelet regimen 
with aspirin and clopidogrel is well documented in patients with acute coronary syndrome 
and patients undergoing percutaneous coronary intervention. Recently the variable response 
to the antiplatelet agents has received considerable attention after several “boxed warnings” 
on clopidogrel. This led to intense controversy on pharmacokinetic, pharmacodynamic, and 
pharmacogenomic issues of antiplatelet drugs, especially clopidogrel. Research use of platelet 
function testing has been successfully validated in identifying new antiplatelet drugs like 
prasugrel and ticagrelor. These platelet function assays are no longer regarded just as a laboratory 
phenomenon but rather as tools that have been shown to predict mortality in several clinical trials. 
It is believed that suboptimal response to an antiplatelet regimen (pharmacodynamic effect) may 
be associated with cardiovascular, cerebrovascular, and peripheral arterial events. There has 
been intense controversy about this variable response of antiplatelet drugs and the role of platelet 
function testing to guide antiplatelet therapy. While the importance of routine platelet function 
testing may be uncertain, it may be useful in high-risk patients such as those with diabetes 
mellitus, diffuse three vessels coronary artery disease, left main stenosis, diffuse atherosclerotic 
disease, and those with chronic renal failure undergoing percutaneous coronary intervention. It 
could also be useful in patients with suspected pharmacodynamic interaction with other drugs 
to assure the adequacy of platelet inhibition. While we wait for definitive trials, a predictive 
prognostic algorithm is necessary to individualize antiplatelet therapy with P2Y12 inhibitors 
based on platelet function assays and genetic testing.
Keywords: platelet function testing, platelet function assay, clopidogrel, coronary artery disease, 
acute coronary syndrome, coronary artery stenting
Background
The optimal use of dual antiplatelet treatment in acute coronary syndromes is evolv-
ing. While the guidelines from the American College of Cardiology and American 
Heart Association are largely based on population-based studies, physicians are 
faced with the management of individual patients who do not fit the published 
guidelines. Dual antiplatelet treatment has been shown to reduce the major adverse 
cardiovascular events after percutaneous coronary interventions (PCI), which is 
believed to be due to the efficacy of antiplatelet drugs.1,2 However, the response vari-
ability of patients to antiplatelet drugs, especially clopidogrel, can lead to pharma-
codynamic failure, which may translate into clinical failure. The use of clopidogrel, 
a thienopyridine, in combination with aspirin is based on American College of 
Cardiology/American Heart Association guidelines on the basis of multiple trials.1,2 
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Dual antiplatelet therapy is recommended for 1 month after 
bare-metal stents and 12 months after drug-eluting stents.3 
Premature cessation of dual antiplatelet therapy is associ-
ated with increased risk for cardiovascular events and stent 
thrombosis,4 a   devastating complication.
The variable response to antiplatelet agents is well-
known and has garnered more attention after several “boxed 
warnings” on clopidogrel. Three sequential boxed warnings 
on clopidogrel have led to intense controversy. There is a 
concern about the suboptimal response to clopidogrel, which 
may be due to genetic polymorphism affecting the metabolic 
pathways and generation of the active metabolite leading 
to decreased pharmacodynamic effect. However, it is not 
clear if the pharmacodynamic failure by platelet function 
assay (PFA) translates into decreased clinical efficacy. It is 
believed that the suboptimal response to antiplatelet regimen 
(pharmacodynamic effect) may be associated with cardio-
vascular, cerebrovascular, and peripheral arterial events.5,6 
There has been intense controversy in regard to this variable 
response of antiplatelet drugs and the role of platelet function 
testing to guide antiplatelet therapy. This review will focus 
on the pharmacokinetic and pharmacodynamic aspects of 
antiplatelet drugs (thienopyridines and nonthienopyridines) 
and role of platelet function testing in guiding therapy.
Pharmacokinetics of antiplatelet 
drugs; P2Y12 receptor antagonist
Thienopyridine drugs, such as ticlopidine, clopidogrel, and 
prasugrel, and the nonthienopyridine ticagrelor bind to the 
P2Y12 adenosine diphosphate (ADP) receptor to initiate the 
clinical response. Ticlopidine, clopidogrel, and   prasugrel are 
prodrugs that require biotransformation to active   metabolites 
for their final effect on platelet aggregation, whereas 
ticagrelor does not require metabolic activation to elicit its 
antiplatelet effect. Ticagrelor and its active metabolites are 
approximately equally potent. It is well-known that clopi-
dogrel has a substantial variability in pharmacodynamic 
response among 15%–40% patients.7–12
Thienopyridines are rapidly absorbed and metabolized in 
the intestine and liver to generate active metabolites for the 
inhibition of platelet activation. These active metabolites bind 
to the P2Y12 receptor on the platelet leading to irreversible 
platelet inhibition. Ticagrelor, a nonthienopyridine, and its 
metabolite cause reversible platelet inhibition with equal 
potency. The half-life of ticagrelor is approximately 7 hours 
(9 hours for the active metabolite). All thienopyridines 
require the CYP450 system to convert the prodrugs to active 
metabolites, but the pathways leading to active metabolites 
are different. Ticagrelor, a nonthienopyridine, is mainly 
metabolized by CYP3A4 of the CYP450 system.
The pharmacokinetics of ticlopidine has not been well 
investigated. Maximum plasma concentration is reached in 
1–3 hours after a single oral dose of 250 mg and steady state 
after 3–5 days.13 Ticlopidine is metabolized by at least five 
main pathways,14 leading to a minimum of 13 different metab-
olites, the majority of which are inactive with only one of 
the metabolites expressing its antiplatelet effect.13 A maximal 
level of clopidogrel active metabolite is reached in 1 hour15,16 
and the plasma concentration of clopidogrel active metabolite 
is dose dependent up to 600 mg.16–18   Maximum concentration 
of the active metabolite of   prasugrel is reached 30 minutes 
after dosing.10,17,19 Clopidogrel is metabolized by two different 
pathways. One pathway leads to 85% clopidogrel to inactive 
metabolite, while the remainder goes through a second path-
way by two oxidation steps via CYP450 enzymes. CYP2C19 
is involved in both of these steps.20,21 Since CYP2C19 is the 
predominant enzyme, the genetic variation in this enzyme 
leads to variable production of active metabolites, leading to 
variable response.22,23 In contrast, prasugrel undergoes a rapid 
de-esterification to an intermediate thioactone, which is then 
converted into active metabolite by a single CYP-dependent 
step24–26 and pharmacokinetics and pharmacodynamics are 
not affected by genetic variation of CYP polymorphism.20,23 
Ticagrelor and cangrelor are reversible inhibitors of P2Y12 
ADP receptor and do not require metabolic activation. 
Ticagrelor is rapidly absorbed and undergoes enzymatic 
degradation to its active metabolite27,28 with maximum active 
metabolite and pharmacodynamic effects in 1–3 hours and 
plasma half-life of 7–9 hours. Cangrelor reach steady state 
within 30 minutes of the start of intravenous infusion. It 
has very short plasma half-life of 9 minutes.29 Elinogrel30 
is a direct reversible P2Y12 receptor blocker. It is the first 
  antiplatelet agent that may be administered either intrave-
nously or orally which may facilitate a smooth transition 
from acute to long-term therapy. This is not approved for use 
in USA at the time of writing.
Pharmacodynamics of antiplatelet 
drugs; P2Y12 receptor antagonist
Platelet activation occurs with the rupture of plaque in the 
culprit vessel or at the implantation of coronary stents. It 
involves several platelet activators, including thrombin, 
thromboxane A2, and ADP that work through two   receptors 
on the platelets, namely P2Y1 and P2Y12.31 Although the 
binding of ADP to both of these receptors is necessary for 
platelet aggregation, P2Y12 is the predominant receptor 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
66
Sharma et alVascular Health and Risk Management 2012:8
responsible for activation and aggregation of platelets via 
activation of glycoprotein (GP) IIb/IIIa receptor.32,33 Binding 
of ADP to these P2Y12 receptors stimulates activation of GP 
IIb/IIIa receptors leading to enhanced platelet degranulation, 
thromboxane production, and platelet aggregation.34 Therefore, 
during coronary intervention, P2Y12 inhibition and inhibition 
of thromboxane production with acetylsalicylic acid is needed, 
in addition to antithrombotic regimens.35 Despite this dual 
antiplatelet therapy with acetylsalicylic acid and clopidogrel, 
15%–40% of patients show poor pharmacodynamic response 
as determined by ADP-induced platelet aggregation.9,27,28,36 
Also, many trials have shown that such a low inhibition of 
platelets with poor pharmacodynamic response may lead to 
higher risk of stent thrombosis in such patients.5,37–39
At the present time, there are three approved thienopyri-
dines and one nonthienopyridine for use after coronary artery 
stenting. Ticlopidine is not   clinically used much due to its 
side effect profile. There is little   published data on its phar-
macodynamic effect and little is known about the interaction 
between the plasma concentration of its active metabolites 
and its pharmacodynamic effect.   Maximum platelet inhibi-
tion occurs 3–4 days after daily dosing in healthy volunteers 
and recovery of platelets occurs 3–4 days after discontinu-
ation. The combination of ticlopidine and aspirin has been 
shown to increase platelet inhibition.40,41
The maximal pharmacodynamic effect of clopidogrel, 
with an average 30% inhibition of platelet aggregation, occurs 
at 4–5 hours after oral loading of 300 mg of clopidogrel.7–9,14,42 
PFAs have shown poor pharmacodynamic effect in 15%–40% 
patients.7–12 Doubling the loading dose from 300 to 600 mg 
results in maximal inhibition of platelet aggregation at 
2–3 hours with additional average increase of 10%–15% 
inhibition of platelet aggregation.12,18,43–45
Enhanced inhibition of platelet aggregation (IPA) with pra-
sugrel was documented in a small substudy of Trial to Assess 
Improvement in Therapeutic Outcome by   Optimizing Platelet 
Inhibition with Prasugrel (TRITON-TIMI [Thrombolysis In 
Acute Myocardial infarction] 38).46 Maximal inhibition of 
platelet aggregation inhibition with prasugrel was observed 
promptly within 15–30 minutes and 60%–70% inhibition of 
platelet aggregation within 2–4 hours.7,9,10,17,47 Peak inhibi-
tion of platelet aggregation after dosing with prasugrel was 
achieved with a mean of 84.1% ± 9.2%. Prasugrel loading with 
60 mg was associated with rapid onset of inhibition of platelet 
aggregation by 1 hour with approximately 90% of patients 
having more than 50% inhibition of platelet aggregation by 
1 hour.7 Patients who are poor responders to clopidogrel 
respond adequately to prasugrel7,48 and during the mainte-
nance phase switching from clopidogrel to prasugrel with or 
without loading dose further improves the pharmacodynamics 
effect.36,48 The maximum IPA effect of ticagrelor was reached 
around 2 hours and was maintained for at least 8 hours after 
loading of 180 mg and inhibition is sustained with mainte-
nance dose of 90 mg twice per day. The mean maximum IPA 
following the last dose of ticagrelor was 88%.27,28 Cangrelor 
is an intravenous direct-P2Y12 inhibitor and maximum 
pharmacodynamics effect is attained in 15 minutes with rapid 
reversal on discontinuation.29
Evaluation of pharmacodynamic 
effect by platelet function assay (PFA)
Recently, three sequential warnings, including a “boxed 
warning” for clopidogrel,49 have led to intense   controversy 
regarding pharmacokinetic, pharmacodynamic and 
  pharmacogenomic issues of antiplatelet drugs. These boxed 
warnings were concerned with the sub optimal antiplatelet 
effect of clopidogrel, due to its need for biotransforma-
tion by CYP450 to an active metabolite. Patients with the 
  hypofunctioning CYP2C19 alleles have shown higher rates of 
cardiovascular events among those undergoing PCI in acute 
coronary syndromes.22 This warning further   emphasized the 
need to identify such genetic polymorphism and   encouraged 
the use of alternative antiplatelet agents. This warning fol-
lowed an open label, yet to be published, study  of 40 healthy 
volunteers, including ten individuals with varying degrees of 
CYP2C19 function, including poor metabolizer, intermedi-
ate metabolizer, and extensive and ultrarapid metabolizer 
groups.50 These individuals were tested with either a 300 mg 
loading dose and 75 mg maintenance or a 600 mg loading 
dose and 150 mg maintenance dose of clopidogrel. End points 
were concentration of active metabolite (pharmacokinetic 
issue) and inhibition of platelet aggregation (pharmacody-
namic issue) by PFA. The main finding was decreased expo-
sure to active metabolites and increased platelet aggregation 
in the poor metabolizer group compared with other groups.
PFAs
The following statement underscores the discussion   regarding 
PFA: “Do we manage hypertension without monitoring blood 
pressure? Do we manage diabetes mellitus without monitor-
ing glucose? Do we manage warfarin without monitoring 
INR [international normalized ratio]? So why do we use 
antiplatelet regimen without monitoring platelet function 
testing?”52 Unfortunately, approximately 30% of patients with 
acute coronary syndrome undergoing PCI and treated with 
clopidogrel had ,30% inhibition of platelet aggregation.51 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
67
Platelet function testing in coronary artery interventionsVascular Health and Risk Management 2012:8
Sharma et al emphasized the need of PFA to recognize such 
hypo- or nonresponders.52 Moreover, there are several studies 
(see Table 2) supporting the role of PFA based on outcome 
studies. There are many different types of PFAs, which have 
methodologies ranging from simple to complex. Different 
methods evaluating platelet function revolve around mea-
surement of platelet aggregation, platelet reactivity, platelet 
receptor expression, measurement of platelet-released fac-
tors on activation, and intracellular platelet signaling. Often 
the question is about the extent of the ideal inhibition of 
platelet aggregation needed for effective clinical efficacy. 
While there is no standard definition of hyporesponsiveness, 
nonresponsiveness, or resistance to antiplatelet drugs based 
on platelet function testing, it is important to identify these 
hypo- or nonresponders to clopidogrel by PFA.
Hyporesponsiveness to clopidogrel can be secondary to 
several factors, including age, body mass index, diabetes, 
dyslipidemia, chronic renal disease, genetic polymorphism, 
and pharmacodynamic interaction with concomitant use 
of other drugs. In patients on a long-term dual antiplatelet 
regimen, guidelines have recommended the use of proton 
pump inhibitors (PPIs)53 to prevent gastrointestinal bleed-
ing.   However, there is an ongoing debate about the increase 
in major adverse cardiovascular events when PPIs are used 
in conjunction with clopidogrel, leading to the US Food and 
Drug Administration (FDA) warning that one PPI (omepra-
zole) reduces the antiplatelet activity of clopidogrel by 50%. 
Such strong pharmacodynamic interaction between clopi-
dogrel and a PPI underscores the need for an objective test-
ing to exclude the attenuation of antiplatelet effect through 
the use of concomitant drugs such as omeprazole.
The role of the concurrent PPI use with clopidogrel and 
their effect on platelet function were assessed in analysis 
of Prasugrel In Comparison to Clopidogrel for Inhibition 
of Platelet Activation and Aggregation and TRITON-
TIMI 38.36,54 These trials showed that PPIs lowered the 
inhibition of platelet aggregation significantly in patients 
taking a PPI and clopidogrel simultaneously. The associa-
tion between PPI use, inhibition of platelet aggregation, and 
clinical outcome was assessed by analysis of the Prasugrel 
In Comparison to Clopidogrel for Inhibition of Platelet 
activation and Aggregation and TRITON-TIMI 38 trials by 
O’Donoghue et al.55 In this study, no association was found 
between the use of PPI and clinical outcome for patients 
treated with clopidogrel and prasugrel. However, FDA 
warnings began a debate in the medical community that has 
often centered on the decreased efficacy of clopidogrel with 
concomitant use of PPIs.56
Variable platelet inhibition occurs as a result of genetic 
polymorphism, leading to different levels of active metabolite 
availability, which in turn leads to variable platelet inhibi-
tion that can be recognized by PFA. The underlying genetic 
variability is due to variation in alleles (nucleotides). One 
important and well-recognized genetic polymorphism is 
the CYP2C19 polymorphism. Mega et al investigated the 
association of CYP2C19 and plasma concentration of 
clopidogrel metabolite and its pharmacodynamic effect on 
platelet function in healthy volunteers.22 This association of 
this genetic role of CYP2C19 polymorphism translated into 
cardiovascular outcomes in a subgroup of 1477 patients in 
the trial “to assess improvement in therapeutic outcome by 
optimizing platelet inhibition with Prasugrel-TIMI 38.”  22 
Carriers with one hypofunctioning allele of CYP2C19 had 
a decreased level of clopidogrel metabolite with reduction 
in antiplatelet activity by platelet function testing. Conse-
quently, there was an increased risk of cardiovascular death, 
acute myocardial infarction or stroke in carriers of the 
hypofunctioning allele of CYP2C19. Furthermore, those 
with the CYP2C19*2 allele had a three-fold increase of stent 
thrombosis. While genetic studies are important in evalu-
ating CYP2C19 polymorphism,57 polymorphism of gene 
ABCB1, polymorphism of CYP3A4, CYP3A5, CYP2B6, or 
genetic polymorphism of P2Y12 receptors,58 the end result 
is a variable inhibition of platelet aggregation in response 
to clopidogrel. Such attenuation of the antiplatelet effect of 
clopidogrel can be measured by PFA. While the importance 
of routine platelet function testing may be uncertain, it may 
be useful in high-risk patients such as those with diabetes 
mellitus, diffuse three vessels coronary artery disease, left 
main stenosis, diffuse atherosclerotic disease, chronic renal 
failure or acute coronary syndromes.59 Moreover, there may 
be suboptimal platelet inhibition in such high-risk patients 
due to pharmacodynamic interaction with other drugs. Mul-
tiple studies, as described below and listed in Table 2, support 
the argument that adequate platelet inhibition is required for 
thienopyridines for reducing cardiovascular events. There are 
several methods used to report high platelet reactivity in the 
clinical trials. These tests use different indices to report plate-
let reactivity, which include light transmittance aggregometry 
(LTA), VerifyNow, vasodilator-stimulated phosphoprotein 
(VASP), Plateletworks, Innovance PFA P2Y IMPACT R 
assay, and PFA-100 (as shown in Table 1).
Outcome studies
There are multiple small-size studies and one major outcome 
study (Table 2) based on PFAs. These studies   examined 
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if suboptimal platelet inhibition translated into major 
  cardiovascular events, using different methodologies. Gur-
bel et al investigated high platelet reactivity by LTA to ADP 
and clot strength, a measure of thrombin-induced fibrin, 
and platelet interaction by thrombelastography.60 This study 
included 192 patients undergoing PCI and postclopidogrel 
treatment and found that high platelet reactivity by LTA 
(63% ± 12% versus 56% ± 15%) was associated with higher 
ischemic events (P = 0.02). Similarly, Bliden et al reported 
high platelet reactivity by LTA in elective PCI patients treated 
Table 2 Outcome studies with different inhibition of platelet aggregation
Study Study patients Clopidogrel dose Platelet function  
assay
Platelet reactivity  
measure
End-point 
prediction
Matetzky et al6 STEMI-PCI 
patients: 60
300 mg post- PCI LTA 
(ADP induced  
aggregation)
Patients stratified  
into 4 quartiles
MACE at 6 months 
P , 0.01
Gurbel et al60 ELLECTIVE PCI,  
patients: 192
300/600 mg post PCI LTA and TEG Patients stratified  
in different quartiles
MACE at 6 months 
P = 0.02
Bliden et al61 ELLECTIVE PCI,  
patients: 100
75 mg for .1 month LTA and TEG Pre-procedural platelet  
aggregation in patients  
on clopidogrel
MACE at 12 months 
P , 0.001
Bonello et al38 ELLECTIVE PCI,  
patients: 144
300 mg, 24 hours  
prior to PCI
VASP-P PRI . 50% MACE at 6 months 
P , 0.01
Price et al63 ELLECTIVE PCI,  
patients: 380
600 mg, 12 hours  
prior to PCI
VerifyNow PRU . 235 MACE at 6 months 
P = 0.008
Marcucci et al64 ACS- PCI 
patients: 683
600 mg prior to PCI VerifyNow PRU . 240 MACE at 12 months 
CV death P = 0.034 
MI P = 0.004
Migliorini et al62 PCI unprotected  
LM, patients: 215
600 mg prior to PCI LTA Platelet reactivity . 70% MACE at 19.3 months 
P = 0.005
El Ghannudi  
et al65 
ELECTIVE and  
URGENT PCI,  
patients: 461
300 or 600 mg VASP-P PRI . 61% MACE at 9 months 
P = 0.037
Breet et al66 ELLECTIVE PCI,  
patients: 1069
75 mg .5 days or  
300 mg .24 hours prior  
or 600 mg .4 hours  
prior to PCI
LTA, VerifyNow,  
plateletworks,  
IMPACT, Innovance  
PFA and PFA-100
Standard Platelet function  
measurement values
MACE at 12 months 
P values for tests  
shown in Figure 2
Abbreviations: ADP, adenosine diphosphate; LM, left main; LTA, light transmittance aggregometry; CV, cardiovascular; MACE, major adverse cardiovascular events; 
MI, myocardial infarction; PFA, platelet function assay; PRI, platelet reactivity index; PRU, P2Y12 reaction unit; TEG, thrombelastography; VASP-P, vasodilator-stimulated 
phosphoprotein phosphorylation.
Table 1 Platelet function assay (PFA)
Method of PFA High platelet reactivity Comments
LTA (5 micro mol/L ADP) .42.9% aggregation Requires dedicated lab with trained technicians;   
labor and time intensive
LTA (20 micro mol/L ADP) .64.5% aggregation Requires dedicated lab with trained technicians;   
labor and time intensive
VerifyNow 
P2Y12 assay
.236 PRU Fully automated and POC and turnaround time  
for test is 15 minutes. VerifyNow P2Y12 Assay  
(Accumetrics, San Diego, California)
VASP-P .50 PRI Requires a dedicated lab. Measures platelet  
reactivity index. Requires a flow cytometer
Plateletworks assay .80.5% aggregation Semi-automated POC, time dependent;  
Helena Laboratories, Beaumont, Texas
PFA 100
(Collagen/ADP cartridge)
Closure time ,116 seconds POC; Siemens Healthcare Diagnostic GMBH,  
Marburg Germany
IMPACT-R Assay
With and without ADP
.8.4% surface coverage 
.3.0% surface coverage
Extensive sample handing; Matis Medical Inc,  
Beersel, Belgium
Innovance PFA P2Y .299 seconds  POC; Siemens Healthcare Diagnostic GMBH,  
Marburg Germany
Abbreviations: ADP, adenosine diphosphate; LTA, light transmittance aggregometry; POC, point of care; PRI, platelet reactivity index; PRU, P2Y12 reaction unit; VASP-P, 
vasodilator-stimulated phosphoprotein phosphorylation.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
69
Platelet function testing in coronary artery interventionsVascular Health and Risk Management 2012:8
with aspirin and clopidogrel, 23% of patients with high 
platelet reactivity had ischemic events (P , 0.001).61 In the 
other outcome study, by Migliorini, high residual platelet 
reactivity by LTA was evaluated in 215 consecutive patients 
undergoing placement of a drug-eluting stent with loading 
of 600 mg of clopidogrel.62 In that study, the primary end 
point was cardiac mortality and secondary end point was 
stent thrombosis. There was a high residual platelet reactiv-
ity in 18.6% of patients. This high residual platelet reactivity 
after 600 mg clopidogrel bolus was a strong marker of major 
cardiovascular events (P = 0.005).
Price et al evaluated platelet reactivity with VerifyNow 
assay in 380 patients undergoing elective PCI. In these 
patients, the high platelet reactivity was reported as P2Y12 
reaction units (PRU).63 PRU $ 235 had a significantly higher 
rate of cardiovascular death (2.8% versus 0%, P = 0.008) and 
a higher rate of stent thrombosis (4.6% versus 0%, P = 0.004) 
at 6 months. However, another outcome study using Veri-
fyNow for platelet function testing involved 643 patients with 
acute coronary syndrome undergoing PCI.64 In this study, all 
patients received 600 mg loading of clopidogrel and major 
adverse cardiovascular events at 12 months (cardiovascular 
death; P = 0.034, nonfatal myocardial infarction; P = 0.004) 
was higher in patients with higher residual platelet   reactivity; 
PRU . 240.
Bonello et al investigated this issue of high platelet 
reactivity by platelet reactivity index using VASP phos-
phorylation analysis.38 In this study, platelet reactivity pre-
dicted postprocedural major adverse cardiovascular events 
(P , 0.01) in 146 patients undergoing PCI with stents and 
showed a 100% negative predictive value. Similarly, the 
VASP test has demonstrated its predictive value for post-
procedural PCI with clopidogrel in a study of 346 patients 
undergoing PCI with a drug-eluting stent after loading with 
clopidogrel using 300 mg and 600 mg.65
The POPULAR (Do Platelet Function Assays Predict 
Clinical   Outcome in Clopidogrel-Pretreated Patients Under-
going Elective PCI) study evaluated the role of higher platelet 
reactivity by multiple platelet function testing to predict 
clinical outcome.66 This was a prospective, observational 
single-center study of 1069 patients undergoing coronary 
stenting with clopidogrel. In this study, platelet reactiv-
ity was measured in parallel by multiple PFAs, including 
LTA, VerifyNow, VASP, Plateletworks, Innovance PFA P2Y 
IMPACT-R assay, and PFA-100, to predict primary end point 
of all-cause mortality, nonfatal acute myocardial infarction, 
stent thrombosis and ischemic stroke. This study found that 
PFAs, LTA, VerifyNow, Plateletworks, and Innovance PFA 
P2Y predicted the primary end point significantly, as illus-
trated in Figure 1. VASP phosphorylation analysis was not 
used in this comparative study.38
Discussion
A dual antiplatelet regimen including aspirin with clopi-
dogrel, prasugrel, or ticagrelor reduces atherothrombotic 
complications in patients undergoing PCI with coronary 
stents.54,67,68 Much attention has been paid to clopidogrel 
hyporesponsiveness after multiple FDA warnings, without 
consideration of aspirin hyporesponsiveness, which is a 
well-known phenomenon.52,69 However, individual response 
to dual antiplatelet regimens with clopidogrel is variable and 
multiple studies support the hypothesis that variable pharma-
codynamic effect may be responsible for atherothrombotic 
events.6,60,63,64 Moreover, hyporesponsiveness to clopidogrel 
has been found to be an independent predictor of cardiovas-
cular events in patients with ACS undergoing percutaneous 
interventions, especially in patients with CYP2C19 genetic 
polymorphism.22 A major drawback of these studies has 
been small sample sizes with evaluation of platelet func-
tion by a single assay, as described in Table 2. The popular 
“Do Platelet Function Assays Predict Clinical Outcome in 
Clopidogrel-Pretreated Patients Undergoing Elective PCI” 
trial evaluated the ability of multiple PFAs in the prediction 
of atherothrombotic events.66 This study showed that several 
PFAs, including LTA , VerifyNow, Plateletworks, and Inno-
vance PFA, predicted cardiovascular events, as shown in 
Figure 1. Several points of care systems have become avail-
able to assess inhibition of aggregation (Table 1). One of the 
commonly used tests in several previous studies and ongoing 
studies is VerifyNow. This point-of-care PFA correlated well 
with LTA, which is considered the gold standard.70 It is also 
relatively inexpensive and easy to perform with excellent 
reproducibility. Several studies (Table 2) have shown higher 
ischemic event rates with suboptimal platelet inhibition with 
VerifyNow reported as PRU . 230 or high platelet reactivity 
measured by LTA.
Thienopyridines or nonthienopyridines, such as ticagre-
lor, inhibit platelet activation via the P2Y12 ADP receptor 
and the extent of this inhibition is reported as PRU units by 
VerifyNow. The VerifyNow assay uses ADP and PGE1 to 
determine platelet reactivity mediated through ADP recep-
tors and a separate channel using thrombin receptors to 
estimate uninhibited response. This test takes advantage of 
different receptors of platelet stimulated by different ago-
nists. Thrombin receptors are strong platelet activators and 
function independent of P2Y12 ADP receptors. Therefore, 
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the base value (base PRU) is calculated by stimulating these 
receptors to estimate the total possible platelet aggregation, 
as if the patient had never received clopidogrel even in the 
presence of clopidogrel. Then, the extent of platelet inhi-
bition by clopidogrel can be measured by using selective 
ADP agonist to measure P2Y12 ADP receptor inhibition by 
thienopyridines or nonthienopyridines. The percent inhibi-
tion of P2Y12 ADP receptors is determined by the difference 
between base PRU and PRU determined from ADP agonist.52 
However, one needs to understand that the values of the 
absolute PRU is calculated by ADP agonist; base PRU by 
thrombin agonist; and percent inhibition on the difference 
LTA 5 µmol/L ADP
0
No. at risk by platelet reactivity
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Figure 1 Kaplan–Meier analysis.
Notes: Kaplan–Meier analysis is for the event rate of the combined primary end point in patients with and without high on-treatment platelet reactivity as measured by 
multiple platelet function test. Adapted with permission from Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical 
outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754–762. Copyright © 2010 American Medical Association. All rights reserved.
Abbreviations: ADP, adenosine diphosphate; LTA, light transmittance aggregometry.
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of both. It is better to follow the absolute PRU rather than 
the per cent P2Y12 inhibition, as the calculated per cent 
P2Y12 inhibition is derived from value obtained from using 
two different agonists, making a valid comparison difficult.
The PFA to guide and tailor antiplatelet therapy has 
received considerable attention. One of the major limita-
tions in this field is the lack of definitions for hyporesponder 
and nonresponder. Tailored antiplatelet therapy is meant to 
achieve adequate platelet inhibition guided by PFAs. This 
is an important issue for the possibility of using more potent 
antiplatelet drugs, like prasugrel and ticagrelor, in patients 
who are hyporesponders or nonresponders to clopidogrel. 
Moreover, PFAs may be useful to monitor triple antiplatelet 
therapy with adjunctive use of cilostazol71 or adjunctive use 
of omega-3 fatty acids.72
Algorithm to address issue  
of hyporesponders or  
nonresponders to clopidogrel
Physicians must be aware that genetic factors and nongenetic 
factors alter clopidogrel metabolism leading to variable 
Thienopyridine naïve
undergoing PCI
ACS undergoing PCI
Prasugrel* or ticagrelor
or high-dose
clopidogrel**
Clinical or anatomic
high-risk factors***
DM, LM, bifurcation and
multi-vessel  CAD 
Prasugrel* or ticagrelor
or high-dose
clopidogrel**
Platelet function assay
Clopidogrel 600/75
PRU < 230 or IPA > 30%,
continue current 
treatment
PRU > 230 or IPA < 30%
prasugrel* or ticagrelor
or high clopidogrel**
 No clinical or anatomic
high-risk factors***
ELECTIVE PCI
Figure 2 Algorithm based on pharmacodynamic concepts.
Notes: *Contraindicated in patient with history of stroke and TIA. **High-dose clopidogrel option; 600 mg loading and 150 mg daily, guided by platelet function assay. 
***Diabetes mellitus, left main stenosis, diffuse atherosclerotic disease, chronic renal failure, and acute coronary syndromes.
Abbreviations: TIA, transient ischemic attack; ACS, acute coronary syndromes; PCI, percutaneous coronary intervention; DM, diabetes mellitus; LM, left main; CAD, 
coronary artery disease.
inhibition of platelet aggregation. This has been shown to 
translate into adverse outcomes in clinical trials as discussed 
above. At the present time, the evidence base is insufficient to 
recommend routine platelet function testing or routine genetic 
testing. However clinical judgment is required to assess 
higher clinical and angiographic risk factors where being a 
hyporesponder to clopidogrel may lead to a poor outcome 
and tailored antiplatelet therapy or alternative antiplatelet 
agent such as prasugrel or ticagrelor may be considered. 
While there is no expert consensus on routine platelet func-
tion testing or genetic testing, certain guidelines have been 
proposed in high-risk patients with clinical conditions such 
as diabetes mellitus, diffuse three vessels coronary artery 
disease, left main stenosis, diffuse atherosclerotic disease 
or chronic renal failure.59 In these patients, an expert panel 
recommends that platelet function testing or genetic testing 
may be considered to identify and adequately treat clopi-
dogrel hyporesponders.73,74
Due to concern over mortality and morbidity which may 
be attributable to the suboptimal response to antiplatelet 
therapy, there are several alternative approaches to standard 
guidelines. New antiplatelet agents such as prasugrel and 
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ticagrelor have demonstrated superiority in patients with 
acute coronary syndrome.54,68 These new drugs are not 
affected by CYP2C19 genetic variants and are more effec-
tive, with a more predictable pharmacodynamic response 
than the standard dose of clopidogrel. While the ongoing 
trials will expand our understanding of dual antiplatelet 
regimens and the role of PFA, use of point of care testing 
to guide treatment in possible hyporesponders or nonre-
sponders to antiplatelet regimen may be useful. At this 
time, routine clinical use of PFAs to maximize efficacy 
in PCI cannot be recommended, but for selected patients 
it may be wise to consider PFAs such as diabetes, multi 
vessel coronary artery disease, bifurcation stenosis, left 
main disease or acute coronary syndromes as illustrated 
in Figure 2 and Figure 3 below. A predictive prognostic 
algorithm is necessary to individualize antiplatelet therapy 
with P2Y12 inhibitors based on PFAs and genetic testing. 
While we wait for definitive trials, the following algorithm 
may be useful (Figures 2 and 3).
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